Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | terminated | Phase 3 | 79 | PfizerINDUSTRY | 10 | Apr 6, 2023 | clinicaltrials |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer | terminated | Phase 1 / Phase 2 | 75 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT02853604 |
| Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) |
| terminated |
| Phase 3 |
| 110 |
| Advaxis, Inc.INDUSTRY |
| 14 |
| Mar 14, 2023 |
| clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse | terminated | Phase 3 | 1,100 | MorphotekINDUSTRY | 30 | Dec 30, 2022 | clinicaltrials |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations | terminated | Phase 1 | 142 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 21, 2022 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | terminated | Phase 2 | 120 | Marker Therapeutics, Inc.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04672980 | RTX-321 Monotherapy in Patients With HPV 16+ Tumors | terminated | Phase 1 | 9 | Rubius TherapeuticsINDUSTRY | 1 | Dec 8, 2022 | clinicaltrials |
| NCT03801031 | Sexual Dysfunction in Gynecologic Oncology Patients | terminated | Phase 4 | 4 | David BenderOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | terminated | Phase 1 | 7 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | terminated | — | 22 | Repertoire Immune MedicinesINDUSTRY | 1 | Dec 6, 2022 | clinicaltrials |
| NCT02933073 | Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma | terminated | Phase 1 | 8 | UConn HealthOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | terminated | Phase 2 | 6 | Craig L Slingluff, JrOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer | terminated | Phase 1 | 15 | Shanghai East HospitalOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | terminated | Phase 3 | 103 | BayerINDUSTRY | 5 | Jun 30, 2022 | clinicaltrials |
| NCT03827993 | Improving Sexual Health in Gynecologic Cancer Patients | terminated | N/A | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy | terminated | Early Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Jun 14, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 2 | 34 | Translational Research in OncologyOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | terminated | Phase 2 | 25 | Xenetic Biosciences, Inc.INDUSTRY | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | terminated | Phase 2 | 5 | University of South AlabamaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | terminated | Phase 3 | 9 | AGO Research GmbHINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01881451 | Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer | terminated | — | 5 | British Columbia Cancer AgencyOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | terminated | Phase 1 | 11 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03324958 | VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients.(Vire-Brachy) | terminated | N/A | 24 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04367467 | Effect of PARP Inhibitors on Glomerular Filtration Rate | terminated | — | 2 | University of PennsylvaniaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | terminated | Phase 1 | 4 | Fox Chase Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | terminated | Phase 2 | 3 | MorphotekINDUSTRY | 2 | Dec 8, 2021 | clinicaltrials |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | terminated | Phase 2 | 5 | ExcellaBio LLCINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | terminated | Phase 2 | 19 | PharmaMarINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03328013 | Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix(HPVAC) | terminated | — | 191 | University Hospital, BrestOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT02740114 | Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway | terminated | Phase 3 | 105 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT01902966 | Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX) | terminated | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT01170650 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)(PROCEED) | terminated | Phase 3 | 441 | EndocyteINDUSTRY | 0 | Sep 30, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT00911079 | Pilot Study of a Catheter-based Ultrasound Hyperthermia System | terminated | N/A | 13 | University of California, San FranciscoOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00232713 | Uterine Fibroid Pregnancy Registry | terminated | — | 2,360 | Syneos HealthOTHER | 0 | Jul 1, 2021 | clinicaltrials |
| NCT00978874 | Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer | terminated | N/A | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 25, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2023source: clinicaltrials